Study of new therapy for B-cell lymphoma or leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a B-cell lymphoma or B-cell acute lymphoblastic leukemia that has come back or not responded to treatment.
- Your cancer cells must show the CD19 marker (a protein on the surface of cells).
- You are reasonably active and able to care for yourself (ECOG score 0 or 1).
- You have not had certain types of previous cell therapy (like CAR-T) and meet other safety criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (called RJMty19) for people with B-cell lymphoma that has returned or not responded to standard treatments. The therapy aims to find and attack cancer cells.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
This trial tests a new cell therapy called GI001 for patients with certain types of B-cell lymphoma or leukemia that have returned or not responded to previous treatments. It aims to see if this therapy can help control the disease.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
This trial tests a new treatment called RN1701 for patients with certain B-cell lymphomas that have not responded to or have returned after previous treatments. The treatment is given as an injection and aims to target and kill lymphoma cells that have CD19 or CD20 markers on them.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.